Skip to main content

Table 3 Number of patients with PD-L1/PD-1 positive tumors and stroma

From: Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer

  Pre-NAC cohort (n = 6) Post-NAC cohort (n = 17)
Overall PD-L1+ 4 (66.7%) 9 (52.9%)
Intratumoral PD-L1+ 3 (50.0%) 5 (29.4%)
Stromal PD-L1+ 4 (66.7%) 10 (58.8%)
Overall PD-1+ 2 (33.3%) 4 (23.5%)
  1. Values are denoted as the number of patients in each group with percentage of cohort that is PD-L1 or PD-1 positive in the parentheses